Last reviewed · How we verify
Envacgen®
Envacgen is a recombinant protein subunit vaccine designed to stimulate immune responses against specific disease targets through antigen presentation.
Envacgen is a recombinant protein subunit vaccine designed to stimulate immune responses against specific disease targets through antigen presentation. Used for COVID-19 prevention (protein subunit vaccine candidate).
At a glance
| Generic name | Envacgen® |
|---|---|
| Sponsor | Medigen Vaccine Biologics Corp. |
| Drug class | Recombinant protein subunit vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
As a protein subunit vaccine, Envacgen presents recombinant antigens to the immune system to generate both humoral and cellular immune responses. The vaccine is formulated to enhance immunogenicity and promote protective immunity against its target pathogen or disease. This approach avoids the use of live or attenuated organisms, offering a safer vaccine platform.
Approved indications
- COVID-19 prevention (protein subunit vaccine candidate)
Common side effects
- Injection site reactions (pain, erythema, swelling)
- Fever
- Fatigue
- Myalgia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Envacgen® CI brief — competitive landscape report
- Envacgen® updates RSS · CI watch RSS
- Medigen Vaccine Biologics Corp. portfolio CI